Trial · NCT07908563
Dupilumab in Major Depressive Disorder
NCT07908563, Phase 2, Recruiting, Icahn School of Medicine at Mount Sinai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Dupilumab in Major Depressive Disorder. Trials, record NCT07908563. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908563
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Dupilumab in Major Depressive Disorder
- NCT number
- NCT07908563
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 34 participants, estimated
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Major Depressive Disorder
- Interventions
- Dupilumab Injection
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Interleukin-4 receptor alpha (IL-4α) | Baseline and end of treatment at week 9 | To test interleukin-4 receptor alpha (IL-4α) as a novel therapeutic immune target for MDD by quantifying within-subject changes in peripheral immune markers using the Olink platform. |
| Secondary | Response Rate | End of treatment (week 9) | To examine response rate with dupilumab treatment defined as ≥ 50% MADRS total score improvement. The Montgomery-Asberg Depression Rating Scale (MADRS) has 10 items that are based on mood symptoms over the past 7 days. Each item is scored 0 (normal) to 6 (severe depression) with overall total score ranges from 0 - 60. A higher score indicates more severe depression. Response is defined as an improvement in a patient's health status, a reduction in disease activity, or a measurable therapeutic effect following an intervention. |
| Secondary | Remission Rate | End of treatment (week 9) | To examine remission rate with dupilumab treatment defined as a MADRS total score of ≤ 10. The Montgomery-Asberg Depression Rating Scale (MADRS) has 10 items that are based on mood symptoms over the past 7 days. Each item is scored 0 (normal) to 6 (severe depression) with overall total score ranges from 0 - 60. A higher score indicates more severe depression. Remission is defined as a reduction or complete disappearance of the signs and symptoms of a disease. |
| Secondary | The Montgomery-Asberg Depression Rating Scale (MADRS) | Weekly from baseline through end of treatment at week 9 | To examine changes in depression severity as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS). The Montgomery-Asberg Depression Rating Scale (MADRS) has 10 items that are based on mood symptoms over the past 7 days. Each item is scored 0 (normal) to 6 (severe depression) with overall total score ranges from 0 - 60. A higher score indicates more severe depression. |
| Secondary | Change in ventral stratal activation | Baseline and end of treatment at week 9 | To examine changes in ventral stratal activation (brain response) during reward processing (fMRI). |
| Secondary | Internal-External Motivation Task (IMT) | Baseline and end of treatment at week 9 | To examine the relationship between immune modulation and behavioral measures of reward processing and motivation. Reward processing will be measured with the Internal-External Motivation Task (IMT). The IMT is a 15-minute effort-discounting decision-making task. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Effort Discounting Task | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908563
GET https://conductscience.org/api/trials/v1/NCT07908563/registered